SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Lung-Yi Mak, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, DNA polymerase inhibitors for treating hepatitis B: a safety evaluation, Expert Opinion on Drug Safety, 2016, 15, 3, 383

    CrossRef

  2. 2
    Yuri Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Hyo-Suk Lee, Yoon Jun Kim, Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments, Journal of Medical Virology, 2015, 87, 6
  3. 3
    Resat Ozaras, Hawa’a Khodor, Nergul Yetim, Umut Kaan Unal, Yunus Emre Demirhan, Goknil Gultekin, Burak Isal, Monotherapy for hepatitis B infection: a review of treatment options, Expert Review of Anti-infective Therapy, 2015, 13, 12, 1457

    CrossRef

  4. 4
    Aung Myint Thu, Kittiyod Poovorawan, Chatporn Kittitrakul, Apichart Nontprasert, Natthida Sriboonvorakul, Weerapong Phumratanaprapin, Pisit Tangkijvanich, Wattana Leowattana, Polrat Wilairatana, Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand, BMC Pharmacology and Toxicology, 2015, 16, 1

    CrossRef

  5. 5
    Nghia H Nguyen, Huy N Trinh, Thuan T Nguyen, Son T Do, Phuong Tran, Huy A Nguyen, Khanh K Nguyen, Ruel T Garcia, Glen A Lutchman, Mindie H Nguyen, Safety and efficacy of entecavir in adefovir-experienced patients, Journal of Gastroenterology and Hepatology, 2015, 30, 1
  6. 6
    Angeline Oi-Shan Lo, Grace Lai-Hung Wong, Current developments in nucleoside/nucleotide analogues for hepatitis B, Expert Review of Gastroenterology & Hepatology, 2014, 8, 6, 607

    CrossRef

  7. 7
    Isobel D. Ramsay, Jodi M. Lestner, Catherine P. O’Sullivan, Ana L.G. Cruz, Ho Kwong Li, Charlotte I.S. Barker, A worldwide yearly survey of new data in adverse drug reactions, 2014,

    CrossRef